“
TL;DR
It concludes that while viral vectors show great promise and have led to approved therapies, safety concerns and challenges in translating findings to humans remain.
Viruses · 1 author, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It concludes that while viral vectors show great promise and have led to approved therapies, safety concerns and challenges in translating findings to humans remain.
It describes the use of viral vectors, including adenoviral, adeno-associated viral, lentiviral, and oncolytic viruses, for delivering therapeutic genes in cancer, monogenic diseases like SCID and hemophilia, and for vaccines, such as those for COVID-19. The author highlights that numerous preclinical animal studies have provided proof-of-concept, and clinical trials have demonstrated safety and efficacy, leading to the approval of several viral-based drugs and vaccines. Key limitations discussed include the difficulty in translating proof-of-concept from rodents to humans, safety issues related to oncolytic vectors and chromosomal integration, and the lack of commercial success for some therapies like Glybera for a rare disease. The implications are that viral vector diversity is crucial for matching the vector to the therapeutic need, and ongoing engineering is required to improve safety for wider clinical adoption.